Home » Newsletters » BioWorld Science

BioWorld Science

July 6, 2011

View Archived Issues

Preclinical and phase I data show LY-2409021 lowers glucose

Preclinical and clinical phase I and II data reported on antidiabetes agent MK-0893

Scripps Research Institute describes first potent lysophospholipid S1P4 receptor antagonists

GSK discloses new lysophospholipid S1P1 receptor agonists

Chimerix and BARDA reach agreement regarding sole-source contract for smallpox antiviral

Almirall launches Sativex in Germany for treatment of spasticity due to MS

Resverlogix's RVX-297 shows promise in model of multiple sclerosis

Boehringer Ingelheim claims new chemokine CCR2 receptor antagonists

New tachykinin NK3 receptor antagonists designed by Roche

Novel serine/threonine-protein kinase Chk1 inhibitors patented

Lundbeck presents new phosphodiesterase 10A inhibitors

Merck KGaA synthesizes new sphingosine kinase 1 inhibitors

Amgen and UCB join with NASA to test sclerostin-targeted antibody onboard space shuttle Atlantis

GSK receives approvals in Japan for Rotarix and Lamictal

Scancell's SCIB-2 cancer vaccine shows encouraging preclinical results

Sorrento Therapeutics is granted second phase I NIAID grant for MRSA program

Urigen and FDA set next steps for URG-101 study in interstitial cystitis

Chugai receives Japanese approval for additional indication of Pegasys/Copegus combination

Once-monthly minodronic acid formulation approved in Japan

BioLineRx enrolls first subject in phase I BL-1021 trial for neuropathic pain

FDA grants orphan drug status to INNO-206 in soft tissue sarcomas

FDA approves Archimedes Pharma's Lazanda for breakthrough cancer pain

Rib-X Pharmaceuticals and Sanofi enter collaboration to develop new classes of antibiotics

Nuvo Research receives FDA clearance to begin clinical testing of lidocaine spray

RESprotect reacquires North American rights to RP-101

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...